Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1951 1
1952 2
1953 2
1954 2
1955 4
1956 1
1957 1
1958 5
1959 4
1960 4
1961 3
1962 9
1963 17
1964 11
1965 14
1966 15
1967 13
1968 22
1969 17
1970 35
1971 55
1972 52
1973 29
1974 40
1975 36
1976 31
1977 19
1978 34
1979 22
1980 33
1981 50
1982 29
1983 40
1984 44
1985 47
1986 40
1987 27
1988 46
1989 42
1990 40
1991 48
1992 63
1993 50
1994 61
1995 51
1996 56
1997 71
1998 79
1999 93
2000 116
2001 102
2002 112
2003 118
2004 122
2005 115
2006 108
2007 94
2008 90
2009 83
2010 89
2011 79
2012 88
2013 73
2014 68
2015 57
2016 47
2017 44
2018 37
2019 25
2020 22
2021 16
2022 19
2023 13
2024 5
2025 14
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,087 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean ganglionic stimulants (32,037 results)?
Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD).
Pozzi M, Bertella S, Gatti E, Peeters GGAM, Carnovale C, Zambrano S, Nobile M. Pozzi M, et al. Expert Opin Emerg Drugs. 2020 Dec;25(4):395-407. doi: 10.1080/14728214.2020.1820481. Epub 2020 Sep 25. Expert Opin Emerg Drugs. 2020. PMID: 32938246 Free article.
Current pharmacological treatments for ADHD are based on stimulant or non-stimulant medications, targeting dopaminergic and noradrenergic systems in the frontal cortex and dopaminergic system in the basal ganglia. ...
Current pharmacological treatments for ADHD are based on stimulant or non-stimulant medications, targeting dopaminergic and no …
Tics.
Pringsheim T, Davenport WJ, Lang A. Pringsheim T, et al. Curr Opin Neurol. 2003 Aug;16(4):523-7. doi: 10.1097/01.wco.0000084232.82329.47. Curr Opin Neurol. 2003. PMID: 12869813 Review.
Both autoimmune and genetic mechanisms are implicated in the pathophysiology of the syndrome, while neuroimaging studies have identified abnormalities in the composition of the basal ganglia and frontal lobe white matter, as well as alterations in dopaminergic activity. Wh …
Both autoimmune and genetic mechanisms are implicated in the pathophysiology of the syndrome, while neuroimaging studies have identified abn …
Drug-induced extrapyramidal syndromes.
Lader MH. Lader MH. J R Coll Physicians Lond. 1970 Oct;5(1):87-98. J R Coll Physicians Lond. 1970. PMID: 4150143 Free PMC article. Review. No abstract available.
Stimulant side effects: prefrontal/basal ganglia circuit control at dopamine D1/D2 receptors.
Levy F, Dadds MR. Levy F, et al. Australas Psychiatry. 2014 Apr;22(2):179-82. doi: 10.1177/1039856213517948. Epub 2014 Jan 14. Australas Psychiatry. 2014. PMID: 24425798 Review.
BACKGROUND: While side effects of stimulant medication used to treat children for attention deficit hyperactivity disorder have been clinically described as mild but variable, there is little or no research or understanding of biological mechanisms involved. ...RESULTS: Th …
BACKGROUND: While side effects of stimulant medication used to treat children for attention deficit hyperactivity disorder have been …
Ganglionic stimulant action of muscarine.
GYERMEK L, SIGG EB, BINDLER E. GYERMEK L, et al. Am J Physiol. 1963 Jan;204:68-70. doi: 10.1152/ajplegacy.1963.204.1.68. Am J Physiol. 1963. PMID: 13963533 No abstract available.
Caffeine as a psychomotor stimulant: mechanism of action.
Fisone G, Borgkvist A, Usiello A. Fisone G, et al. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. doi: 10.1007/s00018-003-3269-3. Cell Mol Life Sci. 2004. PMID: 15095008 Free PMC article. Review.
The popularity of caffeine as a psychoactive drug is due to its stimulant properties, which depend on its ability to reduce adenosine transmission in the brain. ...Increasing evidence indicates that the psychomotor stimulant effect of caffeine is generated by affect …
The popularity of caffeine as a psychoactive drug is due to its stimulant properties, which depend on its ability to reduce adenosine …
Stimulant-induced adaptations in neostriatal matrix and striosome systems: transiting from instrumental responding to habitual behavior in drug addiction.
Canales JJ. Canales JJ. Neurobiol Learn Mem. 2005 Mar;83(2):93-103. doi: 10.1016/j.nlm.2004.10.006. Neurobiol Learn Mem. 2005. PMID: 15721792 Review.
Converging evidence indicates that repeated exposure to motor stimulants such as cocaine and amphetamine produces marked alterations in network responsiveness of striatal neurons to subsequent challenge with the same stimulant drug. Such alterations, which correlate …
Converging evidence indicates that repeated exposure to motor stimulants such as cocaine and amphetamine produces marked alterations …
Tobacco, coffee, and Parkinson's disease.
Gale C, Martyn C. Gale C, et al. BMJ. 2003 Mar 15;326(7389):561-2. doi: 10.1136/bmj.326.7389.561. BMJ. 2003. PMID: 12637374 Free PMC article. No abstract available.
Drugs, alcohol and driving.
Seppala T, Linnoila M, Mattila MJ. Seppala T, et al. Drugs. 1979 May;17(5):389-408. doi: 10.2165/00003495-197917050-00008. Drugs. 1979. PMID: 37067 Review.
The most significant drugs as regards driving risk are obviously certain antianxiety agents, hypnotics, stimulants, hallucinogens, marihuana, lithium and narcotic analgesics, as well as ganglionic blocking agents, insulin and sulphonylurea derivates. ...Anticholiner …
The most significant drugs as regards driving risk are obviously certain antianxiety agents, hypnotics, stimulants, hallucinogens, ma …
Toward a pathophysiology of attention-deficit/hyperactivity disorder.
Castellanos FX. Castellanos FX. Clin Pediatr (Phila). 1997 Jul;36(7):381-93. doi: 10.1177/000992289703600702. Clin Pediatr (Phila). 1997. PMID: 9241475 Review.
Anatomic neuroimaging studies suggest that the relevant regulatory circuits include the prefrontal cortex and the basal ganglia, which are modulated by dopaminergic innervation from the midbrain and by stimulant medications. ...
Anatomic neuroimaging studies suggest that the relevant regulatory circuits include the prefrontal cortex and the basal ganglia, whic …
3,087 results